| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Editorial Board
|
|
|
|
26 |
S4 |
p. ii-iii
|
artikel
|
| 2 |
LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab
|
Ciardiello, F.
|
|
|
26 |
S4 |
p. iv120
|
artikel
|
| 3 |
LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012
|
Bang, Y-J.
|
|
|
26 |
S4 |
p. iv118
|
artikel
|
| 4 |
LBA-02 High Response Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study
|
Hendifar, A.
|
|
|
26 |
S4 |
p. iv117
|
artikel
|
| 5 |
LBA-06 INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results
|
Pavlakis, N.
|
|
|
26 |
S4 |
p. iv119
|
artikel
|
| 6 |
LBA-10 MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach
|
Arnold, D.
|
|
|
26 |
S4 |
p. iv121
|
artikel
|
| 7 |
LBA-03 Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072)
|
Cunningham, D.
|
|
|
26 |
S4 |
p. iv117
|
artikel
|
| 8 |
LBA-05 Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer
|
Van Cutsem, E.
|
|
|
26 |
S4 |
p. iv118
|
artikel
|
| 9 |
LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer
|
Elez, E.
|
|
|
26 |
S4 |
p. iv120
|
artikel
|
| 10 |
LBA-01 Survival outcomes according to body mass index (BMI): results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer (mCRC)
|
Zafar, Y.
|
|
|
26 |
S4 |
p. iv117
|
artikel
|
| 11 |
LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
|
Van Cutsem, E.
|
|
|
26 |
S4 |
p. iv119
|
artikel
|
| 12 |
O-013 A global risk gene score predicts early and late tumor recurrence after resection of hepatocellular carcinoma
|
Dekervel, J.
|
|
|
26 |
S4 |
p. iv112
|
artikel
|
| 13 |
O-021 Analysis of DNA mismatch repair and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials
|
Zaanan, A.
|
|
|
26 |
S4 |
p. iv116
|
artikel
|
| 14 |
O-001 A phase III trial of aprepitant in colorectal cancer patients receiving oxaliplatin-based chemotherapy (SENRI Trial)
|
Nishimura, J.
|
|
|
26 |
S4 |
p. iv108
|
artikel
|
| 15 |
O-011 Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC)
|
Grothey, A.
|
|
|
26 |
S4 |
p. iv111
|
artikel
|
| 16 |
O-016 Exploratory analysis of tumor growth rate in patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib in the GRID phase 3 trial
|
Kappeler, C.
|
|
|
26 |
S4 |
p. iv114
|
artikel
|
| 17 |
O-006 FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses
|
Cremolini, C.
|
|
|
26 |
S4 |
p. iv109
|
artikel
|
| 18 |
O-014 High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort
|
Sorbye, H.
|
|
|
26 |
S4 |
p. iv113
|
artikel
|
| 19 |
O-003 IMM-101 Extends Survival and Maintains Quality of Life in IMAGE 1, a Randomized, Open-label Phase II Trial comparing Gemcitabine with and without IMM 101 in advanced pancreatic cancer
|
Dalgleish, A.
|
|
|
26 |
S4 |
p. iv108
|
artikel
|
| 20 |
O-015 Is endoscopic submucosal dissection of superficial spreading early gastric cancer safe?
|
Kim, H.M.
|
|
|
26 |
S4 |
p. iv113
|
artikel
|
| 21 |
O-010 KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer
|
Hochster, H.
|
|
|
26 |
S4 |
p. iv111
|
artikel
|
| 22 |
O-012 Nanofluidic digital PCR and extended genotyping of RAS, BRAF and PI3KCA for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies
|
Azuara, D.
|
|
|
26 |
S4 |
p. iv112
|
artikel
|
| 23 |
O-007 Neuropilin 1 (NRP1) may be prognostic and identify a subgroup of Patients with Metastatic Colorectal Cancer (mCRC) who Benefit from Tivozanib + mFOLFOX6 compared to Bevacizumab + mFOLFOX6
|
Benson, A.
|
|
|
26 |
S4 |
p. iv109
|
artikel
|
| 24 |
O-008 Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC)
|
Rimassa, L.
|
|
|
26 |
S4 |
p. iv110
|
artikel
|
| 25 |
O-009 Prognostic value of BRAFV600E and KRAS exon 2 mutations in microsatellite stable stage III colon cancers from patients treated with FOLFOX + /- cetuximab: A pooled analysis from PETACC8 and N0147 trials
|
Taieb, J.
|
|
|
26 |
S4 |
p. iv110
|
artikel
|
| 26 |
O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
|
Garcia-Carbonero, R.
|
|
|
26 |
S4 |
p. iv115
|
artikel
|
| 27 |
O-018 Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)
|
Ruers, T.
|
|
|
26 |
S4 |
p. iv114
|
artikel
|
| 28 |
O-005 Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study
|
Zhu, A.
|
|
|
26 |
S4 |
p. iv109
|
artikel
|
| 29 |
O-019 SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment
|
van Hazel, G.A.
|
|
|
26 |
S4 |
p. iv115
|
artikel
|
| 30 |
O-002 Socio-economic status influences chance of undergoing surgical treatment for pancreatic cancer in the Netherlands
|
Bakens, M.
|
|
|
26 |
S4 |
p. iv108
|
artikel
|
| 31 |
O-017 The prognostic relevance of MRI Tumor Regression Grade versus histopathological complete response in rectal cancer
|
Yu, S.
|
|
|
26 |
S4 |
p. iv114
|
artikel
|
| 32 |
P-221 Acquired 5-FU resistance in CRC models is accompanied by upregulation of VEGF-VEGFR1 signaling, increased migration and invasion that can be attenuated by aflibercept
|
Bouygues, A.
|
|
|
26 |
S4 |
p. iv64
|
artikel
|
| 33 |
P-169 Adjuvant capecitabine: safe and tolerable option for adjuvant treatment in patients with resected pancreas and ampullary adenocarcinoma
|
Rigby, C.
|
|
|
26 |
S4 |
p. iv49
|
artikel
|
| 34 |
P-103 Advanced gastric cancer (AGC) patients treated with S-1 in a Caucasian population. A specialized center experience in Ireland
|
Clifford, D.
|
|
|
26 |
S4 |
p. iv29
|
artikel
|
| 35 |
P-037 Advanced Pancreatic Cancer Patients' Characteristics, Treatment and Outcome Based on Three Age Groups: ≤ 39, 39-74 and ≥ 75, a Report from Single Cancer Institution
|
Gilabert, M.
|
|
|
26 |
S4 |
p. iv10
|
artikel
|
| 36 |
P-266 Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience
|
González-Astorga, B.
|
|
|
26 |
S4 |
p. iv78
|
artikel
|
| 37 |
P-247 A follow-up results of team management approach for XELOX therapy in patients with advanced/recurrent colorectal cancer: the SMILE Study (Study of Metastatic colorectal cancer to investigate Impact of Learning Effect)
|
Shibata, Y.
|
|
|
26 |
S4 |
p. iv72
|
artikel
|
| 38 |
P-231 All RAS mutation predict for poor clinical outcomes after metastasectomy in patients with metastatic colorectal cancer
|
Osumi, H.
|
|
|
26 |
S4 |
p. iv67
|
artikel
|
| 39 |
P-254 A multicentre, non-interventional, post-authorization study to observe in daily clinical practice the treatment duration of patients treated with bevacizumab in 1st line mCRC in Belgium
|
Goeminne, J.-C.
|
|
|
26 |
S4 |
p. iv74
|
artikel
|
| 40 |
P-297 Anastomotic leakage in patients operated for colorectal cancer in a high volume UK centre within an enhanced recovery programme setting
|
Ng, J.
|
|
|
26 |
S4 |
p. iv87
|
artikel
|
| 41 |
P-319 Angiogenesis evaluation in locally advanced colo-rectal and gastric cancers by probe-based Confocal Laser Endomicroscopy (pCLE)
|
Cannizzaro, R.
|
|
|
26 |
S4 |
p. iv93
|
artikel
|
| 42 |
P-256 An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)
|
Dane, F.
|
|
|
26 |
S4 |
p. iv75
|
artikel
|
| 43 |
P-224 A Novel Method of Quantification of Cu2+ Level as the Antioxidative Status Evaluation in Colon Neoplasm
|
Kim, S.H.
|
|
|
26 |
S4 |
p. iv65
|
artikel
|
| 44 |
P-031 A novel reinforcement method for the surface of gastrointestinal metal stent: gas plasma treatment
|
Yoo, I.K.
|
|
|
26 |
S4 |
p. iv8
|
artikel
|
| 45 |
P-305 A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer
|
Vilar, E.
|
|
|
26 |
S4 |
p. iv90
|
artikel
|
| 46 |
P-306 A phase II biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer
|
Schab, A.
|
|
|
26 |
S4 |
p. iv90
|
artikel
|
| 47 |
P-278 A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer (CIRIS study): overall survival analysis
|
Eto, T.
|
|
|
26 |
S4 |
p. iv82
|
artikel
|
| 48 |
P-114 A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma
|
Kaseb, A.
|
|
|
26 |
S4 |
p. iv32
|
artikel
|
| 49 |
P-325 A Phase II trial using a combination of Oxaliplatin, Capecitabine, and Celecoxib with concurrent radiation for newly diagnosed resectable rectal cancer: COX2 expression in relationship to outcomes
|
Araujo-Mino, E.
|
|
|
26 |
S4 |
p. iv95
|
artikel
|
| 50 |
P-161 A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment
|
Samalin, E.
|
|
|
26 |
S4 |
p. iv47
|
artikel
|
| 51 |
P-312 A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab in Patients with KRAS Wild Type Metastatic Colorectal Cancer
|
Huhn, R.
|
|
|
26 |
S4 |
p. iv92
|
artikel
|
| 52 |
P-311 A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)
|
Ducreux, M.
|
|
|
26 |
S4 |
p. iv91
|
artikel
|
| 53 |
P-255 A randomized, placebo-controlled, double-blind phase II trial of peri-operative cimetidine in early colorectal cancer
|
Jameson, M.
|
|
|
26 |
S4 |
p. iv74
|
artikel
|
| 54 |
P-121 Are There the Distinct Endoscopic Ultrasonography Findings of Gastrointestinal Stromal Tumor?
|
Kim, J.-O.
|
|
|
26 |
S4 |
p. iv34
|
artikel
|
| 55 |
P-057 A retrospective analysis for patients with HER2 positive gastric cancer who were treated with trastuzumab-based chemotherapy
|
Kang, J.H.
|
|
|
26 |
S4 |
p. iv16
|
artikel
|
| 56 |
P-011 ARHI re-expression inhibits subcutaneous xenograft growth and the lung/liver metastases of human gastric cancer cells (BGC823) in nude mice
|
Qiu, J.P.
|
|
|
26 |
S4 |
p. iv3
|
artikel
|
| 57 |
P-204 Array-comparative genome hybridization analysis of primary colorectal cancers and corresponding liver metastases
|
Zurawska, J.
|
|
|
26 |
S4 |
p. iv59
|
artikel
|
| 58 |
P-194 Association of the -4791 A/T and the -4601A/G polymorphisms of the distal promoter of RAD51 gene with a risk of colorectal cancer
|
Majsterek, I.
|
|
|
26 |
S4 |
p. iv56
|
artikel
|
| 59 |
P-014 A Tumor-penetrating Recombinant Protein anti-EGFR-iRGD Enhance Efficacy of Paclitaxel in 3D multicellular spheroids and Gastric Cancer in vivo
|
Sha, H.
|
|
|
26 |
S4 |
p. iv4
|
artikel
|
| 60 |
P-062 Baseline neutrophil-lymphocyte ratio as a prognostic factor for patients with resectable gastric cancer undergoing adjuvant chemotherapy
|
Laterza, M.M.
|
|
|
26 |
S4 |
p. iv17
|
artikel
|
| 61 |
P-156 Biliary drainage in patients with extrahepatic bile ducts cancer and obstructive jaundice
|
Stoyanov, V.
|
|
|
26 |
S4 |
p. iv44
|
artikel
|
| 62 |
P-154 Biliary tract cancer - Clinical and epidemiological profile Experience of the medical oncology service Cancer Center and Teaching Hospital of Oran
|
Rekai, K.
|
|
|
26 |
S4 |
p. iv44
|
artikel
|
| 63 |
P-138 Biliary tract cancers: epidemiology and prognosis
|
Ben Romdhane, Y.
|
|
|
26 |
S4 |
p. iv39
|
artikel
|
| 64 |
P-327 Biologic Therapy in the management of locally advanced rectal cancer, experience of the National Medical Center November 20, Mexico City
|
Torres, L.
|
|
|
26 |
S4 |
p. iv95
|
artikel
|
| 65 |
P-004 Biomarker-directed therapy for invasive Gastric Cancer: Characterization of a novel regulator of PI3K/AKT/mTOR signaling
|
Singh, S.
|
|
|
26 |
S4 |
p. iv1
|
artikel
|
| 66 |
P-229 Body fat mass and the risk of colorectal polyps in men and women
|
Jarosz, M.
|
|
|
26 |
S4 |
p. iv67
|
artikel
|
| 67 |
P-158 (BREGO) Regorafenib combined with modified (m) GEMOX (Gemcitabine- Oxaliplatin) in patients with advanced biliary tract cancer (BTC): a phase Ib/II randomized trial
|
Assenat, E.
|
|
|
26 |
S4 |
p. iv45
|
artikel
|
| 68 |
P-295 CA 11-19: A Tumor Marker to Detect Colorectal Cancer
|
Overholt, B.
|
|
|
26 |
S4 |
p. iv87
|
artikel
|
| 69 |
P-059 Can high levels of preoperative carbohydrate antigen 19-9 be a predictor of survival in gastric cancer?
|
Garcia, A.
|
|
|
26 |
S4 |
p. iv17
|
artikel
|
| 70 |
P-133 Carcinoma of the amulla of vater: factors predictive of survival
|
Martinez-Galán, J.
|
|
|
26 |
S4 |
p. iv38
|
artikel
|
| 71 |
P-279 Cetuximab as third line treatment of metastatic colorectal carcinoma (mCRC) – 5-year experience from the Institute of Oncology and Radiology of Serbia
|
Spasic, J.
|
|
|
26 |
S4 |
p. iv82
|
artikel
|
| 72 |
P-245 Cetuximab with infusional or oral fluorouracil in 1st line treatment for metastatic colorectal cancer: a comparison study
|
Kotaka, M.
|
|
|
26 |
S4 |
p. iv71
|
artikel
|
| 73 |
P-149 Changes of quality of life in elderly gastrointestinal cancer patients after curative surgery in South Korea.
|
Choi, D.R.
|
|
|
26 |
S4 |
p. iv43
|
artikel
|
| 74 |
P-239 Characterization of Myeloid – Derived Suppressor Cell Subpopulations in Localized Colorectal Adenocarcinoma Patients
|
Hasnis, E.
|
|
|
26 |
S4 |
p. iv69
|
artikel
|
| 75 |
P-232 Characterization of serum HER2 ECD level in patients with metastatic colorectal cancer
|
Taniguchi, H.
|
|
|
26 |
S4 |
p. iv67
|
artikel
|
| 76 |
P-238 Circulating epidermal growth factor-like domain 7 of prognostic importance in patients with metastatic colorectal cancer
|
Hansen, T.
|
|
|
26 |
S4 |
p. iv69
|
artikel
|
| 77 |
P-198 Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib
|
Schirripa, M.
|
|
|
26 |
S4 |
p. iv57
|
artikel
|
| 78 |
P-300 Circulating tumour cell release in the peri-operative setting during curative colorectal cancer surgery
|
Spring, K.
|
|
|
26 |
S4 |
p. iv88
|
artikel
|
| 79 |
P-323 Cisplatin plus capeitabine (CisCape) and radiotherapy (RT) for the neoadjuvant treatment of rectal cancer: final update of previously reported data
|
Formica, V.
|
|
|
26 |
S4 |
p. iv94
|
artikel
|
| 80 |
P-129 Cisplatin plus Gemcitabine in Elderly patients with advanced biliary tract carcinoma: Torrecardenas Hospital Experience
|
Castellon Rubio, V.E.
|
|
|
26 |
S4 |
p. iv37
|
artikel
|
| 81 |
P-310 CLIMB: An EORTC-ESSO Prospective colorectal liver metastasis database with an integrated quality assurance program
|
Evrard, S.
|
|
|
26 |
S4 |
p. iv91
|
artikel
|
| 82 |
P-286 Clinical and laboratory factors in young colorectal cancer patients with liver-only disease treated with upfront CAPOX and Bevacizumab combination – Single institution experience
|
Petrova, V.
|
|
|
26 |
S4 |
p. iv84
|
artikel
|
| 83 |
P-137 Clinical feature of 53 patients with biliary neuroendocrine tumors: Retrospective study for Korean neuroendocrine tumor of gallbladder, extrahepatic biliary tract, and ampulla of Vater
|
Cho, J.H.
|
|
|
26 |
S4 |
p. iv39
|
artikel
|
| 84 |
P-144 Clinical Features and Outcome of Advanced Cholangiocarcinoma
|
Kandel, B.
|
|
|
26 |
S4 |
p. iv41
|
artikel
|
| 85 |
P-250 Clinical Impact and Cost Implication of Routine MMR Protein Immunohistochemistry in High Risk Dukes B Colon Cancer
|
Chiu, K.
|
|
|
26 |
S4 |
p. iv73
|
artikel
|
| 86 |
P-124 Clinical outcome and impact of lymph node level assessment in biliary tract cancers
|
Martinez-Galán, J.
|
|
|
26 |
S4 |
p. iv35
|
artikel
|
| 87 |
P-074 Clinical outcome of doublet and triplet neoadjuvant chemotherapy for marginally and potentially resectable gastric cancer. retrospective single center case control study
|
Kim, J.S.
|
|
|
26 |
S4 |
p. iv20
|
artikel
|
| 88 |
P-063 Clinical outcomes in patients with gastric cancer bleeding as initial presenting symptom
|
Chung, W.C.
|
|
|
26 |
S4 |
p. iv18
|
artikel
|
| 89 |
P-182 Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer – functional imaging is prognostic and provides proof of mechanism
|
Wilson, J.
|
|
|
26 |
S4 |
p. iv53
|
artikel
|
| 90 |
P-005 Clinical significance of Eph, FGFR, and PDGF expressions in advanced gastric cancers
|
Nishi, N.
|
|
|
26 |
S4 |
p. iv2
|
artikel
|
| 91 |
P-092 Clinico- epidemiological and therapeutic profile of gastric adenocarcinoma
|
Boudinar, F.Z.
|
|
|
26 |
S4 |
p. iv26
|
artikel
|
| 92 |
P-209 Clinico-epidemiological profile of colorectal cancer in Algerian patients age 40 and under: Alarming Increase in Incidence
|
Bekouaci, S.
|
|
|
26 |
S4 |
p. iv61
|
artikel
|
| 93 |
P-009 Clinicopathological and epidemiological features of gastric cancer in young patients at Instituto Nacional de Enfermedades Neoplasicas Lima-Perú
|
Pacheco, C.
|
|
|
26 |
S4 |
p. iv3
|
artikel
|
| 94 |
P-087 Clinicopathological characteristics in patients with bone Metastasis in GI Cancers
|
Shimizu, Y.
|
|
|
26 |
S4 |
p. iv24
|
artikel
|
| 95 |
P-243 Clinicopathologic features and survival outcomes of colorectal cancer in young patients: Experience from a cancer institute in Peru
|
Ruiz, R.
|
|
|
26 |
S4 |
p. iv70
|
artikel
|
| 96 |
P-263 Colon Carcinoma stage II: Chemotherapy or Surveillance?
|
Moreira Gomes, R.
|
|
|
26 |
S4 |
p. iv77
|
artikel
|
| 97 |
P-141 Combined versus sequential adjuvant therapy of biliary tract cancer: what is the best option?
|
Cassano, A.
|
|
|
26 |
S4 |
p. iv40
|
artikel
|
| 98 |
P-064 Compliance with the adjuvant chemotherapy according to the extent of gastrectomy in patients with gastric cancer
|
Yu, W.
|
|
|
26 |
S4 |
p. iv18
|
artikel
|
| 99 |
P-260 Complication rate of palliative colonic stenting for metastatic colorectal cancer
|
Bernard, H.
|
|
|
26 |
S4 |
p. iv76
|
artikel
|
| 100 |
P-173 Concomitant statins can be the favorable factor for gemcitabine and erlotinib combination chemotherapy in advanced pancreatic cancer
|
Lee, H.S.
|
|
|
26 |
S4 |
p. iv50
|
artikel
|
| 101 |
P-322 Concomitent radiochemotherapy in elderly patients with locally-advanced rectal cancer
|
Anghel, R.
|
|
|
26 |
S4 |
p. iv94
|
artikel
|
| 102 |
P-273 Concordance of RAS mutation status in CRC patients by comparison of results from circulating tumour DNA and tissue-based testing
|
Scott, R.
|
|
|
26 |
S4 |
p. iv80
|
artikel
|
| 103 |
P-122 Concurrent Chemotherapy and Volumetric Modulated Arc Therapy (VMAT) in carcinoma of the anal canal- Reduction of acute gastrointestinal and genitourinary toxicity
|
Yordanov, K.
|
|
|
26 |
S4 |
p. iv35
|
artikel
|
| 104 |
P-299 Contrast medium marking for gastrointestinal stenting
|
Ninomiya, J.
|
|
|
26 |
S4 |
p. iv88
|
artikel
|
| 105 |
P-227 Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT116 cells through down-regulation of prostaglandin E2 receptor EP4
|
Choi, Y.H.
|
|
|
26 |
S4 |
p. iv66
|
artikel
|
| 106 |
P-021 Cordycepin sensitizes TRAIL-mediated apoptosis through p38 MAPK-dependent and AMPK-independent signaling pathways in human gastric carcinoma AGS cells
|
Park, C.
|
|
|
26 |
S4 |
p. iv6
|
artikel
|
| 107 |
P-189 Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer
|
Pasic, A.
|
|
|
26 |
S4 |
p. iv55
|
artikel
|
| 108 |
P-230 Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in France
|
Taieb, J.
|
|
|
26 |
S4 |
p. iv67
|
artikel
|
| 109 |
PD-017 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)
|
Nishina, T.
|
|
|
26 |
S4 |
p. iv106
|
artikel
|
| 110 |
PD-013 A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC)
|
Heinemann, V.
|
|
|
26 |
S4 |
p. iv104
|
artikel
|
| 111 |
PD-015 A survey on current RAS-mutation testing practices in Europe
|
Boleij, A.
|
|
|
26 |
S4 |
p. iv105
|
artikel
|
| 112 |
PD-007 Clinical outcome of Endoscopic Resection of Rectal Neuroendocrine Tumor- NET registry multicenter study
|
Cho, Y.K.
|
|
|
26 |
S4 |
p. iv102
|
artikel
|
| 113 |
PD-005 Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
|
Palmer, D.
|
|
|
26 |
S4 |
p. iv102
|
artikel
|
| 114 |
PD-016 Developmental therapeutics activity portrait in metastatic colorectal cancer (mCRC): Vall d'Hebron Institute of Oncology Program
|
Grasselli, J.
|
|
|
26 |
S4 |
p. iv105
|
artikel
|
| 115 |
P-166 Decrement of Serum CA 19-9 Concentration after Initial Chemotherapy Predicts Favorable Outcome in Patients with Advanced Pancreatic Cancer
|
Ryu, J.
|
|
|
26 |
S4 |
p. iv48
|
artikel
|
| 116 |
P-168 Definitive 3D concurrent chemoradiotherapy in locally advanced pancreatic cancer
|
Khalaf, M.
|
|
|
26 |
S4 |
p. iv48
|
artikel
|
| 117 |
P-199 Degradation of CONNEXIN 43 in the plasma membrane by autophagy in colon cancer
|
Paulo, J.
|
|
|
26 |
S4 |
p. iv58
|
artikel
|
| 118 |
P-136 De novo malignancy after living donor liver transplantation
|
Shinoda, M.
|
|
|
26 |
S4 |
p. iv39
|
artikel
|
| 119 |
PD-010 Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in CRC models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial
|
Mésange, P.
|
|
|
26 |
S4 |
p. iv103
|
artikel
|
| 120 |
P-018 Desacetyl isovaltratum, an extract from Valeriana, induces G2/M phase arrest and apoptosis in gastric cancer cell lines
|
Zhang, B.
|
|
|
26 |
S4 |
p. iv5
|
artikel
|
| 121 |
P-222 Detection of colorectal dysplasia using fluorescently-labeled lectins
|
Kuo, J.
|
|
|
26 |
S4 |
p. iv64
|
artikel
|
| 122 |
P-210 Detection of epithelial-mesenchymal transition in colorectal cancer in consideration of intratumor heterogeneity
|
Muto, Y.
|
|
|
26 |
S4 |
p. iv61
|
artikel
|
| 123 |
PD-014 First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)
|
Rivera, F
|
|
|
26 |
S4 |
p. iv105
|
artikel
|
| 124 |
PD-006 Gemcitabine and Oxaliplatin (GEMOX) with or without Panitumumab as First-Line Treatment in Advanced Biliary Tract Cancer; final results and subgroup analysis of the Vecti-BIL Study
|
Marino, D.
|
|
|
26 |
S4 |
p. iv102
|
artikel
|
| 125 |
P-251 Diagnosis of malignant lymphoma during at the colorectal cancer surgery
|
Natori, K.
|
|
|
26 |
S4 |
p. iv73
|
artikel
|
| 126 |
P-240 Did the change of mRNA copy numbers in peripheral blood influence their relationship with colorectal cancer patients' prognosis?
|
Liu, Y.
|
|
|
26 |
S4 |
p. iv70
|
artikel
|
| 127 |
P-155 Digestive tract cancers in young adults: epidemiologic study and therapeutic results of a Tunisian Series
|
Meganem, H.
|
|
|
26 |
S4 |
p. iv44
|
artikel
|
| 128 |
PD-002 Impact of the definition of time to event endpoint on randomized clinical trials results in oncology (DATECAN-2): an analysis of 9 pancreatic cancer trials
|
Pam, A.
|
|
|
26 |
S4 |
p. iv101
|
artikel
|
| 129 |
PD-003 Incidence and risk factors of deep venous thrombosis detected by routine surveillance ultrasonography before surgery in patients with gastric cancer
|
Tanizawa, Y.
|
|
|
26 |
S4 |
p. iv101
|
artikel
|
| 130 |
PD-011 Inexpensive biomarkers for determining individuals at increased risk for colorectal cancer and hence have the repeat screening colonoscopy after the first normal earlier than guidelines recommend
|
Metzger, B.
|
|
|
26 |
S4 |
p. iv104
|
artikel
|
| 131 |
PD-018 Modifiable risk factors for colorectal cancer: A multinational case-control study
|
Hrinczenko, B.
|
|
|
26 |
S4 |
p. iv106
|
artikel
|
| 132 |
P-192 DNA methylation profile of APC and DKK2 genes as biomarkers in colorectal cancer patients
|
da Silva, T.
|
|
|
26 |
S4 |
p. iv55
|
artikel
|
| 133 |
P-097 Double tract reconstruction after laparoscopic proximal gastrectomy; its procedure and short-term results
|
Kojima, K.
|
|
|
26 |
S4 |
p. iv27
|
artikel
|
| 134 |
P-193 Downregulation of CDX2 is associated with MMR-deficiency but not recurrence in colon cancer
|
Olsen, J.
|
|
|
26 |
S4 |
p. iv56
|
artikel
|
| 135 |
PD-001 Prognostic value of tumor infiltrating lymphocytes (TILs) in Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC)
|
Kim, J.G.
|
|
|
26 |
S4 |
p. iv101
|
artikel
|
| 136 |
PD-008 Safety and efficacy of desensitization protocols for platinum hypersensitivity reactions
|
Pedersen, K.
|
|
|
26 |
S4 |
p. iv103
|
artikel
|
| 137 |
PD-020 Uplift modeling in selection of patients to either radiotherapy or radiochemotherapy in resectable rectal cancer: reassessment of data from the phase 3 study
|
Wyrwicz, L.
|
|
|
26 |
S4 |
p. iv107
|
artikel
|
| 138 |
PD-009 Use of adjuvant chemotherapy after pancreatoduodenectomy for pancreatic cancer: a nationwide population-based study in the Netherlands
|
Bakens, M.
|
|
|
26 |
S4 |
p. iv103
|
artikel
|
| 139 |
PD-012 Validation study of the 12-gene Recurrence Score (RS) in patients (pts) with stage II and III colon cancer (CC) without adjuvant chemotherapy; SUNRISE Study
|
Ikeda, M.
|
|
|
26 |
S4 |
p. iv104
|
artikel
|
| 140 |
PD-019 What effect does pre-operative Enhanced Recovery Protocol counselling have on post-operative length of stay after colorectal resections?
|
Yoganathan, S.
|
|
|
26 |
S4 |
p. iv106
|
artikel
|
| 141 |
P-233 Economic impact of biomarker-based anti EGFR therapies in metastatic colorectal cancer in Austria
|
Niedersuess-Beke, D.
|
|
|
26 |
S4 |
p. iv68
|
artikel
|
| 142 |
P-336 Effect of radiotherapy on sphincter-sparing operations rate in rectal cancer patients
|
Beznosenko, A.
|
|
|
26 |
S4 |
p. iv97
|
artikel
|
| 143 |
P-216 Effect on colorectal cancer patients' anxiety levels of planned following at home
|
Cavasoglu, F.
|
|
|
26 |
S4 |
p. iv63
|
artikel
|
| 144 |
P-109 Effects of metformin on clinical outcomes in advanced HCC patients receiving sorfenib
|
Casadei Gardini, A.
|
|
|
26 |
S4 |
p. iv30
|
artikel
|
| 145 |
P-172 Efficacy and safety of S-1 and gemcitabine in an unselected Western cohort of patients with unresectable pancreatic cancer
|
Pfeiffer, P.
|
|
|
26 |
S4 |
p. iv50
|
artikel
|
| 146 |
P-206 Efficacy and tolerance of a simplified combination of Streptozotocin and epi-adriamycin in metastatic foregut neuroendocrine tumor (NET)
|
Hirsch, L.
|
|
|
26 |
S4 |
p. iv60
|
artikel
|
| 147 |
P-139 Efficacy of a Sequential Treatment Strategy with GEMOX Followed by FOLFIRI in Advanced Cholangiocarcinoma
|
Sebbagh, S.
|
|
|
26 |
S4 |
p. iv40
|
artikel
|
| 148 |
P-288 Efficacy of Magnetic Marking Clip Method for Pre-operative Localization of Gastrointestinal Tumor
|
Kim, S.H.
|
|
|
26 |
S4 |
p. iv85
|
artikel
|
| 149 |
P-128 Efficacy of Various Endoscopic Transpapillary Sampling Methods for Malignant Biliary Lesions
|
Hyun, J.J.
|
|
|
26 |
S4 |
p. iv37
|
artikel
|
| 150 |
P-127 Efficacy of Y-Shaped Bilateral Self-Expandable Metallic Stent Placement in Patients with Unresectable Hilar Cholangiocarcinoma
|
Hyun, J.J.
|
|
|
26 |
S4 |
p. iv36
|
artikel
|
| 151 |
P-170 Efficiency of minor endoscopic sphincterotomy for biliary stenting in malignant biliary obstruction
|
Kim, J.H.
|
|
|
26 |
S4 |
p. iv49
|
artikel
|
| 152 |
P-135 Endoscopic Changes and Long-term Outcome of Radiotherapy for Helicobacter pylori Negative/Refractory Gastric Marginal Zone B Cell Lymphoma
|
Ryu, S.J.
|
|
|
26 |
S4 |
p. iv38
|
artikel
|
| 153 |
P-075 Endoscopic treatment of type 3 gastric neuroendocrine tumor
|
Lee, K.J.
|
|
|
26 |
S4 |
p. iv21
|
artikel
|
| 154 |
P-023 eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib
|
Gardini, A.C.
|
|
|
26 |
S4 |
p. iv6
|
artikel
|
| 155 |
P-207 Epidemiological and clinical aspects of colorectal cancer: The experience of a single institution in Algeria
|
Abdelkader El Hakim, B.
|
|
|
26 |
S4 |
p. iv60
|
artikel
|
| 156 |
P-016 Epidemiological research on stomach cancer in Morocco
|
Hami, H.
|
|
|
26 |
S4 |
p. iv5
|
artikel
|
| 157 |
P-160 Estimation of autonomic nervous system activity by heart rate and blood pressure variability in patients with gastric and colorectal cancer. Preliminary study
|
Zygulska, A.
|
|
|
26 |
S4 |
p. iv46
|
artikel
|
| 158 |
P-253 EUS before endoscopic management of small Rectal NETs is not essential process
|
Kim, W.C.
|
|
|
26 |
S4 |
p. iv74
|
artikel
|
| 159 |
P-054 Evaluation of driver mutations involving in RAS-RAF/PI3K-mToR pathway in gastric signet ring cell carcinoma
|
Liu, B.
|
|
|
26 |
S4 |
p. iv15
|
artikel
|
| 160 |
P-088 Evaluation of prognostic and predictive factors in second-line treatment with irinotecan based chemotherapy in gastric cancer
|
Biernacka, R.
|
|
|
26 |
S4 |
p. iv25
|
artikel
|
| 161 |
P-248 Evaluation of the use and effectiveness of adjuvant chemotherapy in patients with stage II colon cancer: data from the Hospital of Lithuanian University of Health Sciences
|
Vaitiekus, D.
|
|
|
26 |
S4 |
p. iv72
|
artikel
|
| 162 |
P-191 Exploration of the implication of thymidylate synthase polymorphisms on the risk of colorectal cancer in west Algerian population
|
Aberkane, M.
|
|
|
26 |
S4 |
p. iv55
|
artikel
|
| 163 |
P-022 Expression of Circulating Annexin A2 in Hepatic Diseases and Hepatocellular Carcinoma
|
Elgezawy, E.
|
|
|
26 |
S4 |
p. iv6
|
artikel
|
| 164 |
P-094 FDG PET/CT as a preoperative staging modality for early gastric cancer
|
Oh, H.W.
|
|
|
26 |
S4 |
p. iv26
|
artikel
|
| 165 |
P-241 Feasibility and results of expanded RAS genotyping in an Argentiean public hospital
|
Otero, S.
|
|
|
26 |
S4 |
p. iv70
|
artikel
|
| 166 |
P-190 Feasibility of using MicroRNAs in early detection of recurrence in colon cancer patients
|
Olsen, J.
|
|
|
26 |
S4 |
p. iv55
|
artikel
|
| 167 |
P-246 Feasibility study of sequential adjuvant chemotherapy with three months oxaliplatin-based regimen followed by three months capecitabine in patients with stage III and high risk stage II colorectal cancer: (JSWOG C2)
|
Tanioka, H.
|
|
|
26 |
S4 |
p. iv72
|
artikel
|
| 168 |
P-111 Final results of the GIDEON (Global Investigational of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study according to patient etiology: The Italian experience
|
D'Angelo, S.
|
|
|
26 |
S4 |
p. iv31
|
artikel
|
| 169 |
P-264 First cycle dose calculation in obese patients with colorectal cancers
|
Una Cidon, E.
|
|
|
26 |
S4 |
p. iv77
|
artikel
|
| 170 |
P-178 First-line chemotherapy with gemcitabine in advanced pancreatic cancer: a retrospective single-center analysis
|
Magalhães, H.
|
|
|
26 |
S4 |
p. iv52
|
artikel
|
| 171 |
P-049 First-line cisplatin plus bolus 5- Fluorouracil combination in patients with locally advanced and metastatic esophageal cancer
|
Akyol, M.
|
|
|
26 |
S4 |
p. iv14
|
artikel
|
| 172 |
P-046 Follow-up results of expandable metal stents for malignant esophageal obstruction in 210 cases
|
Moon, H.S.
|
|
|
26 |
S4 |
p. iv13
|
artikel
|
| 173 |
P-038 FRAX597, a PAK1 inhibitor, synergises with gemcitabine in the reduction of pancreatic cancer growth
|
Yeo, D.
|
|
|
26 |
S4 |
p. iv10
|
artikel
|
| 174 |
P-033 Fruit consumption and selected gastrointestinal cancers morbidity in Poland in the years 1990-2012
|
Jarosz, M.
|
|
|
26 |
S4 |
p. iv9
|
artikel
|
| 175 |
P-082 Gastric cancer in Moroccan patients aged 45 years or younger: Clinicopathological features and prognosis
|
Ziani, F.
|
|
|
26 |
S4 |
p. iv23
|
artikel
|
| 176 |
P-084 Gastric cancer – The reality of an institution
|
Saraiva, N.
|
|
|
26 |
S4 |
p. iv23
|
artikel
|
| 177 |
P-096 Gastric Carcinoma and curative surgery predictive factors: Retrospective analysis of 60 Tunisian cases
|
Chraiet, N.
|
|
|
26 |
S4 |
p. iv27
|
artikel
|
| 178 |
P-159 Gastric myoelectric activity disturbances in patients with gastric and colorectal cancer. Preliminary study
|
Zygulska, A.
|
|
|
26 |
S4 |
p. iv46
|
artikel
|
| 179 |
P-179 Gemcitabine plus nab-Paclitaxel in metastatic or locally inoperable pancreatic cancer – a single center experience
|
Vogl, U.
|
|
|
26 |
S4 |
p. iv52
|
artikel
|
| 180 |
P-164 Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future
|
Calegari, M.A.
|
|
|
26 |
S4 |
p. iv47
|
artikel
|
| 181 |
P-220 Genetic Polymorphism of Vitamin D Receptor BsmI, ApaI and CYP27B1, CYP24A1 genes and the risk of colorectal cancer
|
Vidigal, V.
|
|
|
26 |
S4 |
p. iv64
|
artikel
|
| 182 |
P-061 Geographic distribution of gastric cancer and relating risk factors in Ardabil province, Iran
|
Hadavi, M.
|
|
|
26 |
S4 |
p. iv17
|
artikel
|
| 183 |
P-258 Grade III-IV toxicities among elderly stage III colon cancer patients receiving CAPOX or capecitabine
|
van Erning, F.
|
|
|
26 |
S4 |
p. iv75
|
artikel
|
| 184 |
P-110 Hepatocellular carcinoma in elderly patients: Final results of the Italian cohort of GIDEON study
|
Zolfino, T.
|
|
|
26 |
S4 |
p. iv31
|
artikel
|
| 185 |
P-093 HER2 protein over-expression in early stage gastric cancer: correlation with clinicopathological features and survival
|
Yavuzsen, T.
|
|
|
26 |
S4 |
p. iv26
|
artikel
|
| 186 |
P-055 High BIM mRNA levels associated with longer survival in advanced gastric cancer
|
Wu, N.
|
|
|
26 |
S4 |
p. iv15
|
artikel
|
| 187 |
P-337 Histologic analysis of anal sphincter after radiotherapy of rectal cancer
|
Beznosenko, A.
|
|
|
26 |
S4 |
p. iv98
|
artikel
|
| 188 |
P-015 HOTAIR can determine the proliferation and invasiveness of gastrointestinal stromal tumor
|
Lee, S.K.
|
|
|
26 |
S4 |
p. iv4
|
artikel
|
| 189 |
P-307 Immunomodulatory switch maintenance therapy to improve overall survival in metastatic colorectal carcinoma: The phase 3 IMPALA study
|
Arnold, D.
|
|
|
26 |
S4 |
p. iv90
|
artikel
|
| 190 |
P-152 Impact of anemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin
|
Oblak, I.
|
|
|
26 |
S4 |
p. iv43
|
artikel
|
| 191 |
P-153 Impact of comorbidity on survival of patients with cholangiocarcinoma
|
Inga, E.
|
|
|
26 |
S4 |
p. iv44
|
artikel
|
| 192 |
P-079 Impact of disease biology and stage on outcomes for oesophageal and gastric adenocarcinoma (OGA) treated with neoadjuvant chemotherapy
|
Fontana, E.
|
|
|
26 |
S4 |
p. iv22
|
artikel
|
| 193 |
P-268 Impact of optimal morphologic response on survival in patients with KRAS wild-type unresectable colorectal liver metastases receiving an anti-EGFR or anti-VEGF agent
|
Masuishi, T.
|
|
|
26 |
S4 |
p. iv78
|
artikel
|
| 194 |
P-321 Impact of re-irradiation on patients with locally relapse rectal cancer
|
Kozma, E.
|
|
|
26 |
S4 |
p. iv94
|
artikel
|
| 195 |
P-283 Impact of second-line cetuximab-containing therapy in patients with KRAS wild type metastatic colorectal cancer: results from ITACa trial
|
Passardi, A.
|
|
|
26 |
S4 |
p. iv83
|
artikel
|
| 196 |
P-277 Increased Carcinoembryonic antigen (CEA) predicts poor prognosis in patients after neoadjuvant chemotherapy that undergo hepatectomy for liver-only colorectal metastases and especially in those who don't receive post-hepatectomy adjuvant chemotherapy
|
Giakoustidis, A.
|
|
|
26 |
S4 |
p. iv82
|
artikel
|
| 197 |
P-039 Increased expression of monocarboxylate transporters 1 and 4 and carbonic anhydrase IX in pancreatic ductal adenocarcinomas
|
Marques, A.
|
|
|
26 |
S4 |
p. iv11
|
artikel
|
| 198 |
P-215 Induction of apoptosis by 7,8-dihydroxyflavone in human colon cancer HCT-116 cells through activation of p53 and AMPK signaling pathways
|
Yoo, Y.H.
|
|
|
26 |
S4 |
p. iv62
|
artikel
|
| 199 |
P-042 Institutional experience in induction chemotherapy and neoadjuvant IMRT for borderline resectable and locally advanced pancreatic adenocarcinoma
|
de Torres Olombrada, M.V.
|
|
|
26 |
S4 |
p. iv11
|
artikel
|
| 200 |
P-257 Intensity of adjuvant chemotherapy regimens among elderly stage III colon cancer patients
|
van Erning, F.
|
|
|
26 |
S4 |
p. iv75
|
artikel
|
| 201 |
P-162 Interim Results of IMMU-132 (Sacituzumab Govitecan), an Anti-Trop-2 Antibody-Drug Conjugate (ADC), in Patients (pts) with Metastatic Gastrointestinal (GI) Cancers
|
Ocean, A.
|
|
|
26 |
S4 |
p. iv47
|
artikel
|
| 202 |
P-186 International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
|
Philip, P.
|
|
|
26 |
S4 |
p. iv54
|
artikel
|
| 203 |
P-060 Intestinal versus Diffuse Gastric Cancer – Chemoradiation for all or do we need different therapeutic approaches?
|
Garcia, A.
|
|
|
26 |
S4 |
p. iv17
|
artikel
|
| 204 |
P-163 Is KRAS status prognostic or predictive for anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer?
|
Satake, H.
|
|
|
26 |
S4 |
p. iv47
|
artikel
|
| 205 |
P-051 Is Minimally Invasive Esophagectomy Oncologically Safe? results of a case-control study
|
Aral, M.
|
|
|
26 |
S4 |
p. iv14
|
artikel
|
| 206 |
P-287 Is second line aflibercept and FOLFIRI a tolerable and useful down-staging schedule in Ras mutant advanced colorectal cancer in a real world environment?
|
Ocwzarczyk, K.
|
|
|
26 |
S4 |
p. iv85
|
artikel
|
| 207 |
P-237 K-RAS exon 2 mutations in advanced colorectal cancer: are they really so bad prognostic indicators? A phase II mono-institutional retrospective study
|
Dadduzio, V.
|
|
|
26 |
S4 |
p. iv69
|
artikel
|
| 208 |
P-203 KRAS mutational variations and characteristics in colorectal cancer(CRC): Analysis of over 1600 patients in single institute
|
Shinozaki, E.
|
|
|
26 |
S4 |
p. iv59
|
artikel
|
| 209 |
P-313 K-ras mutation as prognostic factor in our patients with rectal cancer
|
Scepanovic, D.
|
|
|
26 |
S4 |
p. iv92
|
artikel
|
| 210 |
P-098 Local advanced gastric cancer: optimization of management
|
Kshivets, O.
|
|
|
26 |
S4 |
p. iv27
|
artikel
|
| 211 |
P-112 Local combination therapy with chemoembolization and microwave ablation in patients with Hepatocellular Carcinoma – a single center experience
|
Fernandes, H.
|
|
|
26 |
S4 |
p. iv32
|
artikel
|
| 212 |
P-025 Long non-coding RNA AOC4P suppressed hepatocellular carcinoma metastasis by inhibiting epithelial-mesenchymal transition
|
Wang, T.-H.
|
|
|
26 |
S4 |
p. iv7
|
artikel
|
| 213 |
P-344 Long-term outcomes after combined chemoradiation therapy of locally advanced rectal cancer, complicated by fistula formation
|
Kolesnik, O.
|
|
|
26 |
S4 |
p. iv99
|
artikel
|
| 214 |
P-006 Loss of ACSS2 expression predict worse survival in patients with gastric cancers
|
Lee, D.
|
|
|
26 |
S4 |
p. iv2
|
artikel
|
| 215 |
P-113 Mammilian target of rapamycin (mTOR) and autophagy in hepatitis C virus-related hepatocellular carcinoma: relation to tumor progression
|
El Aggan, H.
|
|
|
26 |
S4 |
p. iv32
|
artikel
|
| 216 |
P-067 Management of gastric indefinite neoplasia
|
Lim, T.W.
|
|
|
26 |
S4 |
p. iv19
|
artikel
|
| 217 |
P-013 Metastatic Gastric Adenocarcinoma
|
Belmadi, M.
|
|
|
26 |
S4 |
p. iv4
|
artikel
|
| 218 |
P-053 MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer
|
Wei, J.
|
|
|
26 |
S4 |
p. iv15
|
artikel
|
| 219 |
P-157 Mitomycin C, 5-Fluorouracyl and Doxorubicin combination as a second-line chemotherapy in unresectable and metastatic biliary tract carcinoma: results of the first stage
|
Kuchar, A.
|
|
|
26 |
S4 |
p. iv45
|
artikel
|
| 220 |
P-058 Moderate neutropenia is a predictor of better prognosis in metastatic gastric cancer patients treated with the combination regimen of epirubicin, oxaliplatin and 5-fluorouracil
|
Liu, R.
|
|
|
26 |
S4 |
p. iv16
|
artikel
|
| 221 |
P-202 Molecular confocal laser endomicroscopy (CLE) for the assessment of prognosis in colorectal carcinoma, based on evaluation of putative cancer stem cell markers
|
Cherciu, I.
|
|
|
26 |
S4 |
p. iv59
|
artikel
|
| 222 |
P-332 MRI and DWI for TNM-stage assessment of colorectal cancer
|
Ayad, M.
|
|
|
26 |
S4 |
p. iv97
|
artikel
|
| 223 |
P-205 mRNA level of the key components of the Notch signaling pathway in colorectal cancer
|
Kowalczuk, O.
|
|
|
26 |
S4 |
p. iv60
|
artikel
|
| 224 |
P-104 Multi-center phase III trial of Adjuvant Chemoradiotherapy in Stomach Tumors 2 (ARTIST 2)
|
Yoo, K.H.
|
|
|
26 |
S4 |
p. iv29
|
artikel
|
| 225 |
P-302 Multivisceral resections as a treatment option for locally advanced colon cancer with hepatopancreatobiliary involvement
|
Kolesnik, O.
|
|
|
26 |
S4 |
p. iv89
|
artikel
|
| 226 |
P-225 Mutation detection rate among patients with adenomatous polyposis
|
Marrupe, D.
|
|
|
26 |
S4 |
p. iv65
|
artikel
|
| 227 |
P-184 nab-Paclitaxel (nab-P) plus gemcitabine (Gem) for patients with advanced pancreatic cancer who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction: a phase I safety and pharmacokinetics study
|
Riess, H.
|
|
|
26 |
S4 |
p. iv53
|
artikel
|
| 228 |
P-176 Nabpaclitaxel plus gemcitabine as induction chemotherapy (CT) followed by chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
|
Foltran, L.
|
|
|
26 |
S4 |
p. iv51
|
artikel
|
| 229 |
P-316 Neo-adjuvant chemo-radiotherapy in advanced rectal adenocarcinoma: analysis of three different chemo-radiation regimens
|
Ghosh Dastidar, A.
|
|
|
26 |
S4 |
p. iv92
|
artikel
|
| 230 |
P-218 Neo-adjuvant chemotherapy for patients with clinical T4 locally advanced colon cancer: short and long term outcomes
|
Verstegen, M.
|
|
|
26 |
S4 |
p. iv63
|
artikel
|
| 231 |
P-183 Neoadjuvant treatment in borderline resectable pancreatic adenocarcinoma (PA): A single center series
|
Verdaguer Mata, H.
|
|
|
26 |
S4 |
p. iv53
|
artikel
|
| 232 |
P-008 Neoadjuvant treatment in gastric adenocarcinoma
|
Belmadi, M.
|
|
|
26 |
S4 |
p. iv3
|
artikel
|
| 233 |
P-029 Neuroendocrine tumors (NETs): response to chemotherapy by histological grade – experience cneter
|
Gonzalez-Rivas, C.
|
|
|
26 |
S4 |
p. iv8
|
artikel
|
| 234 |
P-196 New perspective for detecting advanced colorectal neoplastic lesions by cytogenetic biomarkers in average risk patients
|
Ionescu, E.M.
|
|
|
26 |
S4 |
p. iv57
|
artikel
|
| 235 |
P-274 Nodal status predict pathologic complete response following preoperative chemotherapy for colorectal liver metastases
|
Calera, L.
|
|
|
26 |
S4 |
p. iv81
|
artikel
|
| 236 |
P-346 Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real life: The CASSIOPEE Study - Interim analysis on patients' characteristics
|
François, E.
|
|
|
26 |
S4 |
p. iv100
|
artikel
|
| 237 |
P-338 Non-Operative Treatment after Neo-Adjuvant Short Course Radiotherapy (The Tlalpan Regime) in a combined modality for Locally Advanced Rectal Cancer with risk factors at the Instituto Nacional de Cancerología (México)
|
Zamora Moreno, J.
|
|
|
26 |
S4 |
p. iv98
|
artikel
|
| 238 |
P-228 Novel 3D Image of Colon Neoplasm Mucosal Tissues using Multiphoton Microscopy
|
Lee, J.M.
|
|
|
26 |
S4 |
p. iv66
|
artikel
|
| 239 |
P-048 Novel treatment of locally advanced esophageal cancer
|
Taghizadeh, A.
|
|
|
26 |
S4 |
p. iv13
|
artikel
|
| 240 |
P-197 Number of CD68(+) macrophages and FasL expression in colon mucosa of patients with inflammatory bowel disease as prognostic factors of colon carcinogenesis
|
Santimov, A.
|
|
|
26 |
S4 |
p. iv57
|
artikel
|
| 241 |
P-150 Ocular toxicities after oxaliplatin: a more frequent toxicity than expected
|
Una Cidon, E.
|
|
|
26 |
S4 |
p. iv43
|
artikel
|
| 242 |
P-003 Oesophageal cancer incidence in Niger: first results from a population-based cancer registry
|
Garba, S.M.
|
|
|
26 |
S4 |
p. iv1
|
artikel
|
| 243 |
P-175 Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma
|
Mahalingam, D.
|
|
|
26 |
S4 |
p. iv51
|
artikel
|
| 244 |
P-294 Opportunistic colorectal cancer screening by colonoscopy – comparative results between two historical cohorts in Bucharest, Romania
|
Ionescu, E.M.
|
|
|
26 |
S4 |
p. iv87
|
artikel
|
| 245 |
P-091 Oral Metronomic Chemotherapy for locally advanced, recurrent metastatic Gastric carcinoma: A Single Group, Prospective, Phase 2 study in India
|
Ramesh, A.
|
|
|
26 |
S4 |
p. iv25
|
artikel
|
| 246 |
P-331 Organ sparing radiotherapy in rectal cancer: definitive chemoradiation is a safe and valid option
|
Brooker, R.
|
|
|
26 |
S4 |
p. iv96
|
artikel
|
| 247 |
P-236 Other RAS mutations incidence in CRCm in routine clinical practice: a center experience
|
Gonzalez Astorga, B.
|
|
|
26 |
S4 |
p. iv68
|
artikel
|
| 248 |
P-181 Outcome Analysis of Upfront Definitive Chemoradiation for Unresectable Pancreatic Adenocarcinoma: A Single Center Experience for over 25 years
|
Koh, H.K.
|
|
|
26 |
S4 |
p. iv52
|
artikel
|
| 249 |
P-317 Outcome of elderly patients with non-metastatic rectal cancer: a retrospective study
|
Bureau, M.-A.
|
|
|
26 |
S4 |
p. iv93
|
artikel
|
| 250 |
P-147 Outcome of second-line chemotherapy (CT2) after first-line CT (CT1) with platinum plus gemcitabine in advanced biliary tract cancer (aBTC): is it worthwhile?
|
Fornaro, L.
|
|
|
26 |
S4 |
p. iv42
|
artikel
|
| 251 |
P-052 Outcomes of minimally invasive esophagectomy versus open esophagectomy for esophageal cancer: a single-center case-control study
|
Santos-Sousa, H.
|
|
|
26 |
S4 |
p. iv14
|
artikel
|
| 252 |
P-072 Overall survival (OS) of patients with advanced gastric cancer (AGC) according to the availability of 5-FU, platinum, taxanes and irinotecan as first, second and third-line chemotherapy
|
Kim, M.J.
|
|
|
26 |
S4 |
p. iv20
|
artikel
|
| 253 |
P-001 Overexpression of HER-2/neu in Resectable Esophageal Squamous Cell Carcinoma
|
Taghizadeh, A.
|
|
|
26 |
S4 |
p. iv1
|
artikel
|
| 254 |
P-019 Overexpression of YAP1 by gene transfection down-regulates α-catenin in human normal gastric epithelial cells (GES-1)
|
Sun, D.
|
|
|
26 |
S4 |
p. iv5
|
artikel
|
| 255 |
P-282 Palliative chemotherapy for patients 70 and above with metastatic colorectal cancer: How Much Chemotherapy is Enough?
|
Bosse, D.
|
|
|
26 |
S4 |
p. iv83
|
artikel
|
| 256 |
P-095 Palliative radiotherapy for haemostasis in irresectable gastric cancer
|
Ayad, M.
|
|
|
26 |
S4 |
p. iv26
|
artikel
|
| 257 |
P-214 Pattern of Dipkoff-2 gene expression in tumoral tissues of colorectal cancer and two tumor tissues of colorectal cancer and three cell lines (HUVEC, SW480 and HCT116)
|
Khodarahmi, F.
|
|
|
26 |
S4 |
p. iv62
|
artikel
|
| 258 |
P-041 Patterns of failure in pancreatic cancer: results review
|
de Torres Olombrada, M.V.
|
|
|
26 |
S4 |
p. iv11
|
artikel
|
| 259 |
P-105 Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study
|
Fuchs, C.
|
|
|
26 |
S4 |
p. iv29
|
artikel
|
| 260 |
P-106 Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study
|
Ohtsu, A.
|
|
|
26 |
S4 |
p. iv29
|
artikel
|
| 261 |
P-131 Percutaneous transhepatic cholangiographic drainage for malignanct biliary obstruction: single centre - 5 year experience
|
Naheed, S.
|
|
|
26 |
S4 |
p. iv37
|
artikel
|
| 262 |
P-047 Perioperative chemotherapy (ECF/FLOT/EOX) for esophagogastric adenocarcinoma: Impact of postoperative chemotherapy on outcome
|
Hoppner, J.
|
|
|
26 |
S4 |
p. iv13
|
artikel
|
| 263 |
P-298 Perioperative Oral Nutritional Support in Colorectal Cancer Patients May Improve Clinical and Health Economics Outcomes
|
Manasek, V.
|
|
|
26 |
S4 |
p. iv88
|
artikel
|
| 264 |
P-056 Peritoneal recurrence or metastasis in relation to outcome in locally advanced and metastatic gastric cancer
|
Yang, Y.
|
|
|
26 |
S4 |
p. iv15
|
artikel
|
| 265 |
P-261 Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC)
|
Cleton, A.
|
|
|
26 |
S4 |
p. iv76
|
artikel
|
| 266 |
P-070 Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS) as first-line therapy in patients with advanced gastro-esophageal cancer
|
Vestermark, L.
|
|
|
26 |
S4 |
p. iv19
|
artikel
|
| 267 |
P-036 Phase II study of gemcitabine and curcumin as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data
|
Soldà, C.
|
|
|
26 |
S4 |
p. iv10
|
artikel
|
| 268 |
P-275 Phase II study of oral tegafur/uracil and leucovorin plus bevacizumab as a first line therapy for elderly patients with advanced or metastatic colorectal cancer
|
Tamagawa, H.
|
|
|
26 |
S4 |
p. iv81
|
artikel
|
| 269 |
P-272 Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab
|
García Alfonso, P.
|
|
|
26 |
S4 |
p. iv80
|
artikel
|
| 270 |
P-177 Phase II trial of capecitabine + nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
|
Scheithauer, W.
|
|
|
26 |
S4 |
p. iv51
|
artikel
|
| 271 |
P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment
|
Hatanaka, K.
|
|
|
26 |
S4 |
p. iv79
|
artikel
|
| 272 |
P-284 Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup
|
Falcone, A.
|
|
|
26 |
S4 |
p. iv84
|
artikel
|
| 273 |
P-116 Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver
|
Goldfarb, P.
|
|
|
26 |
S4 |
p. iv33
|
artikel
|
| 274 |
P-040 Phosphatidylserine Targeted Therapy of Pancreatic Cancer Using SapC-DOPS Nanovesicles
|
Qi, X.
|
|
|
26 |
S4 |
p. iv11
|
artikel
|
| 275 |
P-130 Predictors of malignancy in biliary mucin-producing cystic neoplasms
|
Han, S.Y.
|
|
|
26 |
S4 |
p. iv37
|
artikel
|
| 276 |
P-315 Predictors of pathologic complete response after neoadjuvant treatment in rectal adenocarcinoma
|
Ayadi, M.
|
|
|
26 |
S4 |
p. iv92
|
artikel
|
| 277 |
P-289 Preliminary data of a pilot study of combined stereotactic body radiotherapy (SBRT) and bevacizumab as a radiosensitizer for colorectal liver metastases
|
Chung, H.
|
|
|
26 |
S4 |
p. iv85
|
artikel
|
| 278 |
P-044 Preoperative chemoradiotherapy in locally advanced esophageal carcinoma. A retrospective study from a multidisciplinary oncologic centre
|
Saigí, M.
|
|
|
26 |
S4 |
p. iv12
|
artikel
|
| 279 |
P-296 Preventive intraperitoneal chemotherapy in colon cancers with high risk of recurrence: outcome at 5 years from a prospective study
|
Abid, M.
|
|
|
26 |
S4 |
p. iv87
|
artikel
|
| 280 |
P-083 Prognostic determinants in gastric cancer survival - the importance of metastatic lymph node ratio
|
Nogueira, A.
|
|
|
26 |
S4 |
p. iv23
|
artikel
|
| 281 |
P-341 Prognostic factors and local recurrence on patients with rectal carcinoma
|
Simsek, A.
|
|
|
26 |
S4 |
p. iv99
|
artikel
|
| 282 |
P-123 Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery
|
Slagter, A.
|
|
|
26 |
S4 |
p. iv35
|
artikel
|
| 283 |
P-068 Prognostic factors related to clinical outcomes by self-expandable metal stent due to Malignant Gastric Outlet Obstruction
|
Jeong, D.I.
|
|
|
26 |
S4 |
p. iv19
|
artikel
|
| 284 |
P-119 Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma
|
Lee, S.H.
|
|
|
26 |
S4 |
p. iv34
|
artikel
|
| 285 |
P-065 Prognostic value of carbohydrate tumor markers and inflammation-based markers in gastric cancer
|
Kong, W.
|
|
|
26 |
S4 |
p. iv18
|
artikel
|
| 286 |
P-290 Prognostic value of repeat testing in population screening for CRC - for optimizing efficacy
|
Elsakov, P.
|
|
|
26 |
S4 |
p. iv86
|
artikel
|
| 287 |
P-145 Prospective Phase II Trial of Combination Treatment of Whole Hepatic Irradiation and Hyperthermia in Chemorefractory Numerous Hepatic Metastases of Gastrointestinal Malignancy
|
Yu, J.I.
|
|
|
26 |
S4 |
p. iv41
|
artikel
|
| 288 |
P-244 Prospective study of S-1 + Irinotecan plus bevacizumab as second-line therapy in Japanese patients with metastatic colorectal cancer (KSCC1102)
|
Satake, H.
|
|
|
26 |
S4 |
p. iv71
|
artikel
|
| 289 |
P-309 PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC)
|
Khan, K.
|
|
|
26 |
S4 |
p. iv91
|
artikel
|
| 290 |
P-020 Pseudolarix Acid B induces the apoptosis and inhibits proliferation, migration and invasion on BGC-823 human gastric cancer cells in vitro
|
Wang, D.
|
|
|
26 |
S4 |
p. iv6
|
artikel
|
| 291 |
P-334 Radiological assessments for select patients in neoadjuvant setting in rectal cancer: monoinstitutional experience
|
Murialdo, R.
|
|
|
26 |
S4 |
p. iv97
|
artikel
|
| 292 |
P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT
|
Tempero, M.
|
|
|
26 |
S4 |
p. iv54
|
artikel
|
| 293 |
P-308 RAVELLO trial: Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer
|
Martinelli, E.
|
|
|
26 |
S4 |
p. iv91
|
artikel
|
| 294 |
P-200 Real time image of mitochondria in living colon cancer tissues using probe based multiphoton microscopy
|
Kim, E.S.
|
|
|
26 |
S4 |
p. iv58
|
artikel
|
| 295 |
P-090 Real-world treatment patterns of previously treated advanced gastric and gastroesophageal junction adenocarcinoma (GC) in France
|
Brown, J.
|
|
|
26 |
S4 |
p. iv25
|
artikel
|
| 296 |
P-304 RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy
|
Bokemeyer, C.
|
|
|
26 |
S4 |
p. iv89
|
artikel
|
| 297 |
P-259 Recurrence-free survival according to treatment modality among elderly stage III colon cancer patients
|
van Erning, F.
|
|
|
26 |
S4 |
p. iv76
|
artikel
|
| 298 |
P-034 Red meat consumption and selected gastrointestinal cancers morbidity in Poland in the years 1990-2012
|
Jarosz, M.
|
|
|
26 |
S4 |
p. iv9
|
artikel
|
| 299 |
P-280 Reduction effect of Oxaliplatin-Related sensory neurotoxicity by Goshajinkigan (TJ-107) plus Powdered processed aconite root (TJ-3023)
|
Shindo, Y.
|
|
|
26 |
S4 |
p. iv82
|
artikel
|
| 300 |
P-270 Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong
|
Lam, K.O.
|
|
|
26 |
S4 |
p. iv79
|
artikel
|
| 301 |
P-026 Regulation of Glypican-3 by New MicroRNAs and Implication in Hepatocellular Carcinoma
|
Cartier, F.
|
|
|
26 |
S4 |
p. iv7
|
artikel
|
| 302 |
P-329 Reintroduction of oxaliplatin for patients with metastatic colorectal cancer
|
Ristic, M.
|
|
|
26 |
S4 |
p. iv96
|
artikel
|
| 303 |
P-102 Results of surgical therapy for loco-regional recurrence of gastric cancer
|
Chayka, A.
|
|
|
26 |
S4 |
p. iv28
|
artikel
|
| 304 |
P-303 Results of surgical treatment of colon cancer with implementation of a multimodal enhanced recovery program
|
Makhmudov, D.
|
|
|
26 |
S4 |
p. iv89
|
artikel
|
| 305 |
P-271 Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients: The HGCSG1401 Study -First Report-
|
Yuki, S.
|
|
|
26 |
S4 |
p. iv80
|
artikel
|
| 306 |
P-235 Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
|
Ricci, V.
|
|
|
26 |
S4 |
p. iv68
|
artikel
|
| 307 |
P-167 Risk factors for febrile neutropenia in patients with unresectable pancreatic cancer receiving FOLFIRINOX as the first-line treatment
|
Sasaki, M.
|
|
|
26 |
S4 |
p. iv48
|
artikel
|
| 308 |
P-171 Risk Factors of Progression or Malignancy in Main Duct and Mixed-type Intraductal Papillary Mucinous Neoplasm of the Pancreas
|
Lee, S.H.
|
|
|
26 |
S4 |
p. iv49
|
artikel
|
| 309 |
P-069 Risk Factors of Submucosal or Lymphovascular Metastasis during resection of the Early Gastric Cancer by Endoscopic Submucosal Dissection
|
Shin, J.G.
|
|
|
26 |
S4 |
p. iv19
|
artikel
|
| 310 |
P-318 Risk Factors of Synchronous Inguinal Lymph Nodes Metastasis for Lower Rectal Cancer Involving the Anal Canal
|
Wang, R.
|
|
|
26 |
S4 |
p. iv93
|
artikel
|
| 311 |
P-140 Risk of selected gastrointestinal complications in patients with solid tumors treated with immune checkpoint inhibitors; a Meta analysis
|
Abdel-Rahman, O.
|
|
|
26 |
S4 |
p. iv40
|
artikel
|
| 312 |
P-028 Role of somatostatin analogues in the treatment of neuroendocrine tumors (NETs), experience of Virgen de las Nieves University Hospital
|
González-Rivas, C.
|
|
|
26 |
S4 |
p. iv8
|
artikel
|
| 313 |
P-249 Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003) - an analysis of surgeons vs oncologists
|
Iwanaga, I.
|
|
|
26 |
S4 |
p. iv73
|
artikel
|
| 314 |
P-276 S-1 and oxaliplatin (SOx) in older Western patients with metastatic colorectal cancer (mCRC)
|
Winther, S.
|
|
|
26 |
S4 |
p. iv81
|
artikel
|
| 315 |
P-117 Sarcopenia at First Diagnosis Predicts a Reduced Survival in Patients Affected by Hepatocarcinoma
|
Begini, P.
|
|
|
26 |
S4 |
p. iv33
|
artikel
|
| 316 |
P-085 Second-line palliative chemotherapy for gastric cancer: a single center cohort analysis
|
Wyrwicz, L.
|
|
|
26 |
S4 |
p. iv24
|
artikel
|
| 317 |
P-180 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study
|
Vivaldi, C.
|
|
|
26 |
S4 |
p. iv52
|
artikel
|
| 318 |
P-032 Selenium administration attenuates 5-fluorouracil induced intestinal mucositis
|
Lee, J.M.
|
|
|
26 |
S4 |
p. iv9
|
artikel
|
| 319 |
P-120 Serum alkaline phosphatase level as an early diagnostic tool in colorectal cancer
|
Pavkovic, B.
|
|
|
26 |
S4 |
p. iv34
|
artikel
|
| 320 |
P-081 Serum tumor markers as predictors of overall response rate and clinical benefit in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy
|
Cortez Castedo, S.P.
|
|
|
26 |
S4 |
p. iv22
|
artikel
|
| 321 |
P-142 Severity of Malnutrition Status of Gastrointestinal Cancer: Nutritional Screening and Assessment Registry in Korean Gastroenterointestinal Cancer Patients
|
Kim, E.S.
|
|
|
26 |
S4 |
p. iv40
|
artikel
|
| 322 |
P-012 Significance and relationship between the expression of Nodal-1 and YAP1 with Gastric Carcinogenesis and Metastasis
|
Li, P.
|
|
|
26 |
S4 |
p. iv4
|
artikel
|
| 323 |
P-291 Significance of chemotherapy induced neutropenia as a prognostic factor in colorectal cancer patients
|
An, J.S.
|
|
|
26 |
S4 |
p. iv86
|
artikel
|
| 324 |
P-066 S-1 in combination with epirubicin and oxaliplatin (EOS) in Caucasian patients (pts) with advanced or metastatic gastric cancer (AGC): Results of a phase I study
|
Moehler, M.
|
|
|
26 |
S4 |
p. iv18
|
artikel
|
| 325 |
P-071 Single-center experience with first-line S-1 plus cisplatin chemotherapy for locally advanced unresectable and metastatic gastric and gastroesophageal junction adenocarcinoma in a Caucasian population
|
Petrányi, Á.
|
|
|
26 |
S4 |
p. iv20
|
artikel
|
| 326 |
P-078 Small cell stomach MALT-lymphoma
|
Mallaev, M.
|
|
|
26 |
S4 |
p. iv21
|
artikel
|
| 327 |
P-010 Snail mediates Rab25-induced gastric cancer cell EMT and invasiveness
|
Jeong, B.Y.
|
|
|
26 |
S4 |
p. iv3
|
artikel
|
| 328 |
P-165 Specific changes in fecal microbiota may differentiate Pancreatic Cancer patients from healthy individuals
|
Half, E.
|
|
|
26 |
S4 |
p. iv48
|
artikel
|
| 329 |
P-195 SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer
|
Montal, R.
|
|
|
26 |
S4 |
p. iv56
|
artikel
|
| 330 |
P-080 Staging echoendoscopy in esophagogastric cancer patients ongoing surgery
|
Villaescusa, A.
|
|
|
26 |
S4 |
p. iv22
|
artikel
|
| 331 |
P-342 Standardized Technique of Laparoscopic Extralevator Abdominoperineal Excision (LAP-ELAPE)
|
Hamada, M.
|
|
|
26 |
S4 |
p. iv99
|
artikel
|
| 332 |
P-146 Stenting metastatic bile duct obstruction (BDO): the importance of liver function parameters
|
Bergamino Sirven, M.
|
|
|
26 |
S4 |
p. iv42
|
artikel
|
| 333 |
P-125 Study of multiple neoplasms consist of hematological malignancies and gastrointestinal cancer
|
Natori, K.
|
|
|
26 |
S4 |
p. iv35
|
artikel
|
| 334 |
P-265 Survival benefit of oral tegafur/uracil and leucovorin metronomic chemotherapy as a first line therapy for patients with recurrent or metastatic colorectal cancer. A Study from India
|
Ramesh, A.
|
|
|
26 |
S4 |
p. iv77
|
artikel
|
| 335 |
P-343 Survival of patients with multiple colorectal cancer metastases to the liver after radiofrequency thermal ablation
|
Dubinina, V.
|
|
|
26 |
S4 |
p. iv99
|
artikel
|
| 336 |
P-076 Survival outcome of patient with primary gastric diffuse large B-cell lymphoma: An Institutional experience from developing country
|
Gogia, A.
|
|
|
26 |
S4 |
p. iv21
|
artikel
|
| 337 |
P-108 Systematic evaluation of serum inflammatory markers for prognostication of hepatocellular carcinoma (HCC)
|
Chan, S.
|
|
|
26 |
S4 |
p. iv30
|
artikel
|
| 338 |
P-267 Systemic therapy and surgery improve overall survival compared with surgery alone after curative liver resection of colorectal metastases: a single-center study from Costa Rica
|
Quesada-Soto, P.
|
|
|
26 |
S4 |
p. iv78
|
artikel
|
| 339 |
P-017 Tanshinone IIA could inhibit gastric carcinoma AGS cells through increasing the protein expression levels of p-p38, TNF-α, Bax and CHOP but decreasing p-ERK, TCTP and Bip in vivo
|
Su, C.C.
|
|
|
26 |
S4 |
p. iv5
|
artikel
|
| 340 |
P-345 Temporary stoma rates as a marker of quality in rectal cancer surgery in a high volume UK hospital
|
Yoganathan, S.
|
|
|
26 |
S4 |
p. iv100
|
artikel
|
| 341 |
P-118 Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial
|
Faivre, S.
|
|
|
26 |
S4 |
p. iv34
|
artikel
|
| 342 |
P-024 The association between histone 3 lysine 27 trimethylation and liver fibrosis and cancer: relationship with methyltransferase
|
Bae, W.K.
|
|
|
26 |
S4 |
p. iv7
|
artikel
|
| 343 |
P-126 The cases that were diagnosed malignant lymphoma from gastrointestinal tract of biopsy
|
Natori, K.
|
|
|
26 |
S4 |
p. iv36
|
artikel
|
| 344 |
P-073 The clinical usefulness of pronase bowel preparation before ESD for gastric neoplasm
|
Kim, S.
|
|
|
26 |
S4 |
p. iv20
|
artikel
|
| 345 |
P-212 The cost of survival gain in metastatic colorectal cancer (mCRC) in France
|
Whalen, J.
|
|
|
26 |
S4 |
p. iv61
|
artikel
|
| 346 |
P-213 The cost of survival gain in metastatic colorectal cancer (mCRC) in Spain
|
Whalen, J.
|
|
|
26 |
S4 |
p. iv62
|
artikel
|
| 347 |
P-252 The effectiveness of colonoscopy in early gastric cancer patients who received endoscopic submucosal dissection
|
Jeon, J.H.
|
|
|
26 |
S4 |
p. iv74
|
artikel
|
| 348 |
P-132 The expression characteristics and clinical significance of Ki-67 in gastrointestinal stromal tumors
|
Tang, S.
|
|
|
26 |
S4 |
p. iv38
|
artikel
|
| 349 |
P-223 The first experience in Intraoperative Radiation Therapy for locally advanced or recurrent rectal cancer
|
Potemin, S.
|
|
|
26 |
S4 |
p. iv65
|
artikel
|
| 350 |
P-099 The frequency of positive peritoneal washing in patients with T4a stage gastric cancer: long-term results of “radical” surgery
|
Bayramov, R.
|
|
|
26 |
S4 |
p. iv27
|
artikel
|
| 351 |
P-281 The GERCOR and Köhne prognostic models in metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based first-line therapy: comparison and validation of both models in a real-life setting
|
Bruixola, G.
|
|
|
26 |
S4 |
p. iv83
|
artikel
|
| 352 |
P-148 The impact of comorbidities in deciding the first dose of chemotherapy in gastrointestinal tumours
|
Una Cidon, E.
|
|
|
26 |
S4 |
p. iv42
|
artikel
|
| 353 |
P-301 The impact of perioperative hemotransfusions on short-term outcomes after surgical treatment of colon cancer
|
Kolesnik, O.
|
|
|
26 |
S4 |
p. iv89
|
artikel
|
| 354 |
P-262 The impact of variations in KRAS codon 12 and 13 point mutation on the efficacy of cytotoxic chemotherapy for metastatic colorectal cancer (CRC)
|
Nakayama, I.
|
|
|
26 |
S4 |
p. iv77
|
artikel
|
| 355 |
P-226 The influence of change in methodology on the responding rate in the colorectal cancer screening program
|
Samardzic, S.
|
|
|
26 |
S4 |
p. iv66
|
artikel
|
| 356 |
P-234 The Intestinal Stem Cell Marker SOX9 Predicts Relapse of Stage II Colon Cancer Patients
|
Espersen, M.
|
|
|
26 |
S4 |
p. iv68
|
artikel
|
| 357 |
P-324 The Neutrophil-Lymphocyte index in patients with advanced rectal and its association as a factor of pathological response to treatment with chemoradiation
|
Ramirez-Ramirez, M.D.L.
|
|
|
26 |
S4 |
p. iv95
|
artikel
|
| 358 |
P-293 The outcomes of the fecal occult blood testing for colorectal cancer in one local hospital in Chile: results of a first two-year international collaborative study between Chile and Japan
|
Tsubaki, M.
|
|
|
26 |
S4 |
p. iv87
|
artikel
|
| 359 |
P-333 The place of endorectal ultrasound in the management of rectal lesions
|
Ayad, M.
|
|
|
26 |
S4 |
p. iv97
|
artikel
|
| 360 |
P-035 The plasminogen receptor P11 contributes to KRAS-driven invasiveness of pancreatic cancer cells and is upregulated in human pancreatic tumors
|
Bydoun, M.
|
|
|
26 |
S4 |
p. iv9
|
artikel
|
| 361 |
P-292 The Polyp Manager: a new tool to report polyps during colonoscopy in a complete and time-efficient way. A pilot study
|
van de Meeberg, M.
|
|
|
26 |
S4 |
p. iv86
|
artikel
|
| 362 |
P-045 The pretreatment Controlling Nutritional Status (CONUT) score as an independent prognostic factor in patients with clinical Stage I-III esophageal squamous cell carcinoma
|
Toyokawa, T.
|
|
|
26 |
S4 |
p. iv12
|
artikel
|
| 363 |
P-134 The prevalence and fate of the defunctioning stoma in anal cancer
|
Poynter, L.
|
|
|
26 |
S4 |
p. iv38
|
artikel
|
| 364 |
P-027 Therapeutic drug monitoring of imatinib in GIST patients: a tunisian series
|
Meganem, H.
|
|
|
26 |
S4 |
p. iv7
|
artikel
|
| 365 |
P-242 The relationship between serum inflammatory markers and the presence of weight loss and quality of life in refractory metastatic colorectal cancer patients
|
Wyrwicz, L.
|
|
|
26 |
S4 |
p. iv70
|
artikel
|
| 366 |
P-100 The Rhesus D - negative phenotype is one of the major risk factors for postoperative complications after gastrectomy for gastric carcinoma
|
Baušys, A.
|
|
|
26 |
S4 |
p. iv28
|
artikel
|
| 367 |
P-174 The role of gastroenterologists in providing initial information on treatment options for patients with pancreatic cancer (PC) in the United States and Europe: a global quantitative survey
|
Das, K.
|
|
|
26 |
S4 |
p. iv50
|
artikel
|
| 368 |
P-050 The role of radiotherapy or chemoradiotherapy for oligo-recurrence of esophageal cancer after curative resection or chemoradiotherapy
|
Matsumoto, T.
|
|
|
26 |
S4 |
p. iv14
|
artikel
|
| 369 |
P-219 The role of the putative tumor suppressor protein spinophilin in colorectal cancer
|
Stiegelbauer, V.
|
|
|
26 |
S4 |
p. iv64
|
artikel
|
| 370 |
P-320 The role of the status for KRAS mutation as a biomarker in only metastatic rectal cancer
|
Byeon, S.
|
|
|
26 |
S4 |
p. iv94
|
artikel
|
| 371 |
P-208 The Therapeutic Effect of Irreversible Electroporation Ablation in Colon Cancer Animal Model
|
Choi, H.S.
|
|
|
26 |
S4 |
p. iv61
|
artikel
|
| 372 |
P-002 The therapeutic effect of irreversible electroporation according to tissue properties of upper gastrointestinal tract: feasibility study for esophageal neoplasm
|
Choi, H.S.
|
|
|
26 |
S4 |
p. iv1
|
artikel
|
| 373 |
P-217 The use of neo-adjuvant chemotherapy for locally advanced colon cancer in the Netherlands
|
Verstegen, M.
|
|
|
26 |
S4 |
p. iv63
|
artikel
|
| 374 |
P-007 The validation study of tissue specimen for limitation of endoscopic submucosal dissection indication criteria in gastric cancer
|
Choi, H.S.
|
|
|
26 |
S4 |
p. iv2
|
artikel
|
| 375 |
P-107 Topoisomerase II Alpha (TopoIIα) As A Prognostic Biomarker In Hepatocellular Carcinoma
|
El Zawahry, H.
|
|
|
26 |
S4 |
p. iv30
|
artikel
|
| 376 |
P-339 Total Mesorectal (Chemo) Radiation (TMRT) with integrated Mesorectal boost followed by TME for preoperative therapy for locally advanced rectal cancers
|
Thawani, N.
|
|
|
26 |
S4 |
p. iv98
|
artikel
|
| 377 |
P-115 Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity
|
Marsico, V.
|
|
|
26 |
S4 |
p. iv32
|
artikel
|
| 378 |
P-086 Trastuzumab induced cardiotoxicity in Her2 positive metastatic oeso-gastric cancers
|
Eusen, Y.
|
|
|
26 |
S4 |
p. iv24
|
artikel
|
| 379 |
P-043 Treatment intensification of neoadjuvant therapy in locally advanced esophageal cancer by addition of 2 cycles of induction chemotherapy prior to chemoradiation– an Indian experience
|
Saha, S.
|
|
|
26 |
S4 |
p. iv12
|
artikel
|
| 380 |
P-030 Treatment of GIST: a single center experience In Constantine, Algeria
|
Bensalem, A.
|
|
|
26 |
S4 |
p. iv8
|
artikel
|
| 381 |
P-285 Treatment of metastatic colorectal cancer. Experience of Centro Javeriano de Oncología of Hospital Universitario San Ignacio, Bogotá, Colombia
|
Natera Melo, A.K.
|
|
|
26 |
S4 |
p. iv84
|
artikel
|
| 382 |
P-089 Treatment of metastatic gastric cancer with docetaxel-irinotecan combination: Virgen de las Nieves University Hospital experience
|
Conde, V.
|
|
|
26 |
S4 |
p. iv25
|
artikel
|
| 383 |
P-077 Trigger factor in stomach MALT-lympoma
|
Mallaev, M.
|
|
|
26 |
S4 |
p. iv21
|
artikel
|
| 384 |
P-101 Tumor differentiation is a risk factor for lymph node metastasis in patients with gastric cancer
|
Baušys, A.
|
|
|
26 |
S4 |
p. iv28
|
artikel
|
| 385 |
P-151 Understanding distress in gastrointestinal cancer patients to improve a multidisciplinary approach.
|
Milani, A.
|
|
|
26 |
S4 |
p. iv43
|
artikel
|
| 386 |
P-326 Usefulness of Carcinoembryonic Antigen (CEA) as Prognosis Factor in Patients with Stage III Rectal Cancer Treated with Neo- adjuvant Chemoradiotherapy
|
Luna-Pérez, P.
|
|
|
26 |
S4 |
p. iv95
|
artikel
|
| 387 |
P-340 Value of Pelvic Index for prediction of anastomotic leakage after laparoscopic low anterior resection in male rectal cancer
|
Tsuruta, A.
|
|
|
26 |
S4 |
p. iv98
|
artikel
|
| 388 |
P-143 Weight Loss during chemotherapy in patients with advanced Oesophagogastric (OG) and Hepatobiliary-Pancreatic (HPB) cancers is not a surrogate for disease progression
|
Oikonomopoulos, G.
|
|
|
26 |
S4 |
p. iv41
|
artikel
|
| 389 |
P-328 Which is the best first approach for liver-only synchronic metastasis rectal cancer?
|
Ghanem, I.
|
|
|
26 |
S4 |
p. iv96
|
artikel
|
| 390 |
P-201 XRCC1, XRCC3, XPD DNA repair gene polymorphisms as risk factors involved in colon cancer carcinogenesis. A Romanian case-control study
|
Procopciuc, L.M.
|
|
|
26 |
S4 |
p. iv58
|
artikel
|
| 391 |
Scientific Committee of ESMO 17th World Congress on Gastrointestinal Cancer
|
|
|
|
26 |
S4 |
p. v
|
artikel
|
| 392 |
Table of Contents
|
|
|
|
26 |
S4 |
p. vi
|
artikel
|
| 393 |
Title Page
|
|
|
|
26 |
S4 |
p. iv
|
artikel
|
Tijdschrift beschrijving